Practical aspects in the management of hypokalemic periodic paralysis

Jacob O Levitt, Jacob O Levitt

Abstract

Management considerations in hypokalemic periodic paralysis include accurate diagnosis, potassium dosage for acute attacks, choice of diuretic for prophylaxis, identification of triggers, creating a safe physical environment, peri-operative measures, and issues in pregnancy. A positive genetic test in the context of symptoms is the gold standard for diagnosis. Potassium chloride is the favored potassium salt given at 0.5-1.0 mEq/kg for acute attacks. The oral route is favored, but if necessary, a mannitol solvent can be used for intravenous administration. Avoidance of or potassium prophylaxis for common triggers, such as rest after exercise, high carbohydrate meals, and sodium, can prevent attacks. Chronically, acetazolamide, dichlorphenamide, or potassium-sparing diuretics decrease attack frequency and severity but are of little value acutely. Potassium, water, and a telephone should always be at a patient's bedside, regardless of the presence of weakness. Perioperatively, the patient's clinical status should be checked frequently. Firm data on the management of periodic paralysis during pregnancy is lacking. Patient support can be found at http://www.periodicparalysis.org.

References

    1. Lehmann-Horn F, Rudel R, Jurkat-Rott K. Non-dystrophic myotonias and periodic paralyses. In: Engel AG, editor. Myology. 3. New York: McGraw-Hill; 2004. pp. 1257–1300.
    1. Venance SL, Jurkat-Rott K, Lehmann-Horn F, Tawil R. SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide. Neurology. 2004;63:1977.
    1. Editorial Staff. Potassium Supplements (Systemic) In: Klasco RK, editor. USP DI® Drug Information for the Health Care Professional. 26. Greenwood Village, Colorodo: Thomson Micromedex; 2006. pp. 2483–90.
    1. Rose BD. Clinical physiology of acid-base and electrolyte disorders. 4. New York: McGraw-Hill, Inc; 1994. pp. 808–812.
    1. Griggs RC, Resnick J, Engel WK. Intravenous treatment of hypokalemic periodic paralysis. Arch Neurol. 1983;40:539–40.
    1. Tawil R, McDermott MP, Brown R, Jr, Shapiro BC, Ptacek LJ, McManis PG, Dalakas MC, Spector SA, Mendell JR, Hahn AF, Griggs RC. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol. 2000;47:46–53. doi: 10.1002/1531-8249(200001)47:1<46::AID-ANA9>;2-H.
    1. Tawil R, Moxley RT, 3rd, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology. 1993;43:1105–6.
    1. Paisley KE, Tomson CR. Calcium phosphate stones during long-term acetazolamide treatment for epilepsy. Postgrad Med J. 1999;75:427–8.
    1. Liu Z, Braverman LE, Malabanan A. Thyrotoxic periodic paralysis in a Hispanic man after the administration of prednisone. Endocr Pract. 2006;12:427–431.
    1. Gebhardt SE, Thomas RG. Home and Garden Bulletin Number 72. Beltsville, Maryland: United States Department of Agriculture, Agricultural Research Service, Nutrient Data Laboratory; Nutritive Value in Foods. Accessed June 10, 2006.
    1. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997;60:1316–25. doi: 10.1086/515454.
    1. Schapira AH, Griggs RC, eds . Blue Books of Practical Neurology Muscle Diseases. Vol. 24. Boston: Butterworth-Heinemann; 1999. pp. 135–175.
    1. Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. Muscle Nerve. 2004;30:114–7. doi: 10.1002/mus.20068.
    1. Kim JB, Kim MH, Lee SJ, Kim DJ, Lee BC. The genotype and clinical phenotype of korean patients with familial hypokalemic periodic paralysis. J Korean Med Sci. 2007;22:946–51.
    1. Robinson JE, Morin VI, Douglas MJ, Wilson RD. Familial hypokalemic periodic paralysis and Wolff-Perkinson-White syndrome in pregnancy. Can J Anaesth. 2000;47:160–4.
    1. Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, Tristani-Firouzi M, Tawil R, Griggs RC, CINCH investigators The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. 2006;129:8–17. doi: 10.1093/brain/awh639.
    1. Miller TM, Dias da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, McManis P, Griggs RC, Angelini C, Servidei S, Petajan J, Dalakas MC, Ranum LP, Fu YH, Ptácek LJ. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004;63:1647–1655.
    1. Periodic Paralysis Association [Accessed January 12, 2008]
    1. Periodic Paralysis News Desk [Accessed January 12, 2008]
    1. Muscular Dystrophy Association [Accessed January 12, 2008]
    1. Periodic Paralysis Association Research Registry [Accessed January 12, 2008]
    1. Heine R, Pika U, Lehmann-Horn F. A novel SCN4A mutation causing myotonia aggravated by cold and potassium. Hum Mol Genet. 1993;2:1349–1353. doi: 10.1093/hmg/2.9.1349.
    1. Rudel R, Lehmann-Horn F. Paramyotonia, potassium-aggravated myotonias and periodic paralyses. 37th ENMC International Workshop, Naarden, The Netherlands, 8–10 December 1995. Neuromuscular Disord. 1997;7:127–132. doi: 10.1016/S0960-8966(96)00418-X.
    1. Ricker K, Moxley RT, 3rd, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol. 1994;51:1095–1102.
    1. Ptacek LJ, Tawil R, Griggs RC, Meola G, McManis P, Barohn RJ, Mendell JR, Harris C, Spitzer R, Santiago F, et al. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology. 1994;44:1500–1503.
    1. Lerche H, Heine R, Pika U, George AL, Jr, Mitrovic N, Browatzki M, Weiss T, Rivet-Bastide M, Franke C, Lomonaco M, et al. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. J Physiol. 1993;470:13–22.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa